Evidence continues to mount suggesting that GLP-1 drugs may help people cut back on cigarettes, drinking and opioid use. As the medications — which include semaglutide and tirzepatide — have grown in popularity, anecdotal reports have emerged of people who said they no longer felt the urge to drink alcohol or use drugs while taking a GLP-1. Peer-reviewed studies have since followed. “An accumulating body of studies are showing positive potential for using GLP-1s for substance use,” said Christian Hendershot, director of clinical research at the USC Institute for Addiction Science in Los Angeles. Most of this research has focused on people with alcohol use disorder. A new study, published Wednesday in The BMJ, casts a much wider net, looking at the effects GLP-1s have on other substance use disorders, including cannabis, cocaine, nicotine and opioids. In the study, researchers analyzed patient records from more than 600,000 people in a Department of Veterans Affairs database.…